

1. Record Nr.	UNINA9910629282403321
Titolo	Liver disease in clinical practice // edited by Tim Cross
Pubbl/distr/stampa	Cham, Switzerland : , : Springer, , [2022] ©2022
ISBN	9783031100123 9783031100116
Edizione	[2nd ed.]
Descrizione fisica	1 online resource (424 pages)
Collana	In Clinical Practice
Disciplina	617.96
Soggetti	Liver Diseases Clinical Medicine
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Includes index.
Nota di contenuto	Intro -- Preface -- Contents -- Contributors -- Chapter 1: Assessment of Liver Function -- Case Study -- An Overview of Anatomy and Functions of the Liver -- Metabolic -- Immunologic -- Common Risk Factors for Deranged Liver Enzyme Tests -- Alcohol -- Metabolic Factors -- Risk Factors for Viral Hepatitis -- Drug-Induced Liver Injury -- Interpretation of Liver Function Tests -- Initial Approach to Potential Liver Disease -- Parenchymal Liver Screen -- Tests of Hepatocellular Damage -- Serum Aminotransferases (ALT and AST) [3, 4] -- Alkaline Phosphatase (ALP) -- Isolated GGT Elevation -- Bilirubin -- Test of Liver Synthetic Function -- Prothrombin Time -- Albumin -- Platelets -- Liver Fibrosis -- Special Circumstances: Pregnancy [6] -- References -- Chapter 2: Acute Liver Failure -- Introduction -- Epidemiology -- Prognosis -- Initial Resuscitation and Referral -- Respiratory Support -- Cardiovascular Support -- Neurological Support -- Coagulopathy Management -- Metabolic Support -- Renal Support -- Microbiological Considerations -- Liver Transplantation -- Plasma Exchange -- Extra-Corporeal Liver Support -- References -- Chapter 3: Drug-Induced Liver Injury -- Introduction and Epidemiology -- Risk Factors Associated with DILI -- Pathogenesis -- Case Definitions and Phenotypes of Idiosyncratic DILI -- Patterns of DILI -- Hepatocellular DILI -- Cholestatic DILI -- Specific Phenotypes of DILI --

Drug-Induced Autoimmune Hepatitis -- Checkpoint Inhibitor-Induced Liver Injury (ChILI) -- Causality Assessment -- Severity of DILI -- Stepwise Approach to Clinical Diagnosis of DILI -- Role of Liver Biopsy -- Role of Pharmacogenetic Testing -- Management -- References -- Chapter 4: Liver Decompensation and Acute on Chronic Liver Failure -- Introduction -- ACLF and Prognostication Models -- Pathogenesis of Acute-on-Chronic Liver Failure.

Principles of Management of Liver Decompensation -- General Approach to Management -- Variceal Haemorrhage -- Ascites -- Encephalopathy -- Alcoholic Hepatitis -- Infections and Sepsis -- Renal Failure and Hepatorenal Syndrome -- Adrenal Failure -- Coagulopathy -- Summary -- References -- Chapter 5: Portal Hypertension: Varices -- Clinical Case -- Pathophysiology of Portal Hypertension -- Classification of Portal Hypertension -- Portal Hypertension Due to Cirrhosis -- Development of Varices -- Manifestations of Varices -- Diagnosis of Varices -- Surveillance of Varices -- Treatment -- Treatment to Prevent Development of Varices -- Prophylactic Treatment to Prevent First Variceal Haemorrhage -- Treatment of Variceal Haemorrhage -- Medical Therapy -- Endoscopic Variceal Ligation -- Failure of First Line Therapy -- TIPSS Placement -- Secondary Prophylaxis -- Gastric Varices -- References -- Chapter 6: Frailty and Sarcopenia in Cirrhosis -- Introduction -- Pathophysiology of Frailty and Sarcopenia -- Measuring Frailty and Its Clinical Impact -- Karnofsky Performance Status (KPS) -- Fried Frailty Index (FFI) -- Liver Frailty Index (LFI) -- CT Muscle Measurement -- Frailty Interventions and the Future -- Summary -- References -- Chapter 7: Non-alcoholic Fatty Liver Disease -- Introduction -- Pathophysiology -- Natural History -- Making the Diagnosis of NAFLD -- Clinical History and Examination -- Blood Tests -- Imaging -- Non-invasive Markers of Fibrosis in NAFLD -- Scoring Systems -- Transient Elastography -- The Role of Liver Biopsy -- Management -- Weight Loss and Lifestyle Modification -- Interventions for Metabolic Syndrome +/- Secondary Benefits on the Liver -- Liver-Specific Agents -- Monitoring Cirrhosis, Liver Transplantation and the Multidisciplinary Approach -- Future Directions -- References -- Chapter 8: Chronic Hepatitis B -- Introduction.

Epidemiology -- Preventative Measures -- Screening -- Immunisation -- Diagnosis and Disease Work-Up -- Virology -- Structure -- Viral Replication -- Natural History and Immunology -- Acute HBV Infection -- Phases of Chronic HBV Infection -- Management of Hepatitis B -- Nucleos(t)ide Analogs (NUCs) -- Pegylated-Interferon (Peg-IFN) -- Patient Selection/Who to Treat -- e-Antigen Positive -- e-Antigen Negative -- Special Populations -- Cirrhotic -- Immunosuppressed -- Pregnancy -- Biomarkers -- HCC Surveillance -- Future Therapies -- Conclusion -- References -- Chapter 9: Chronic Hepatitis C -- Case Study -- Background -- Presentation -- Investigations -- Management -- Summary -- References -- Chapter 10: Autoimmune Hepatitis and Overlap Syndromes -- Introduction -- Epidemiology -- Aetiology and Pathogenesis -- Clinical Features -- Diagnosis -- Biochemical -- Immunological -- Pathology -- Differential Diagnosis -- Scoring Systems Used in Diagnosis -- Other Investigations -- Management -- Who Should Be Treated? -- Pharmacological Treatment -- Managing Medication Side Effects and Treatment Considerations -- Assessing Response to Treatment, Treatment Cessation, Outcomes, and Prognosis -- Liver Transplantation -- Special Circumstances -- Pregnancy -- Overlap Syndromes -- PBC-AIH Overlap -- PSC-AIH Overlap -- References -- Chapter 11: IgG4-Related Hepato-Pancreato-Biliary Disease -- Introduction -- Disease Phenotypes -- Pathophysiology --

Epidemiology -- Disease Associations -- Demographics and Clinical Presentation -- Laboratory Parameters -- Radiological Features -- Histopathological Characteristics -- Diagnosis -- Disease Monitoring -- Management -- Induction Treatment -- Maintenance Treatment -- Outcome -- References -- Chapter 12: Hereditary Haemochromatosis -- Background -- Iron Pathophysiology -- Disease Expression -- Diagnosis -- Treatment.

Non-HFE Haemochromatosis -- Conclusion -- References -- Chapter 13: Pregnancy and Liver Disease -- Introduction -- Normal Physiology in Pregnancy -- Pregnancy Related Liver Diseases -- Hyperemesis Gravidarum -- Intrahepatic Cholestasis of Pregnancy -- Pre-eclampsia/Eclampsia/HELLP Syndrome -- Acute Fatty Liver of Pregnancy (AFLP) -- Hepatic Haemorrhage and Rupture -- Non-pregnancy Related Liver Diseases -- Cirrhosis and Portal Hypertension -- Hepatitis B and C Virus Infection and Pregnancy -- Autoimmune Hepatitis and Pregnancy -- Liver Transplantation -- Liver Disease De Novo in Pregnancy -- Acute Viral Infections and Pregnancy -- Pregnancy and Thrombosis -- Gallstones in Pregnancy -- Summary -- References -- Chapter 14: The Orphan Liver Disease -- Porphyria -- Overview -- Classification of Porphyrias -- Alpha-1-Antitrypsin Deficiency -- Overview -- Genetics and Epidemiology -- Clinical Presentation -- Diagnosis -- Treatment -- Cystic Fibrosis and Liver Disease -- Overview -- Investigations -- Treatment -- References -- Chapter 15: Fontan-Associated Liver Disease (FALD) -- The Evolving Fontan Procedure -- Defining Fontan-Associated Liver Disease -- Fontan Circulatory Dynamics -- The Timescale of Events -- Clinical Presentation -- Diagnosing Cirrhosis in FALD -- Biochemical Markers -- Non-invasive Composite Scores of Liver Disease -- Radiological Imaging -- Elastography -- Portal Hypertension -- Hepatocellular Carcinoma -- Transplantation: Heart Versus Combined Heart-Liver Transplant -- FALD Screening -- Recommended Therapeutic Approaches -- References -- Further Readings -- Chapter 16: Diagnosis and Management of Hepatocellular Carcinoma -- Introduction -- Diagnosis of Hepatocellular Carcinoma -- Current Treatment Modalities for Treatment of Hepatocellular Carcinoma -- The Role of HCC Surveillance in at Risk Patients.

The Role of Liver Transplantation in the Management of HCC -- The Role of Downstaging -- Treatment on the Waiting List -- Liver Transplantation as Salvage Therapy -- Delisting HCC Patients -- Improving Existing Therapies -- Systemic Therapy -- Getting More from Sorafenib -- Conclusion -- References -- Chapter 17: Liver Transplantation -- Introduction -- Candidates -- Indications for Liver Transplantation -- Prognostic Scoring Systems for End-Stage Liver Disease -- The Model of End-Stage Liver Disease (MELD) -- Modification of MELD (MELD-Na) -- The United Kingdom Model for End-Stage Liver Disease (UKELD) -- Super-Urgent LT -- Malignant Liver Disease -- Absolute and Relative Contraindications to LT -- Pre-transplant Assessment -- Cardiopulmonary Assessment -- Renal Assessment -- Imaging -- Nutritional Assessment -- Liver Graft Allocation -- Liver Transplant Surgery -- Post-transplant Care -- Primary Graft Non-function -- Acute Cellular Rejection (ACR) -- Post-transplantation Infections -- Vascular Complications -- Biliary Complications -- Long-Term Follow-Up -- Prognosis -- Bibliography -- Chapter 18: The Hepatological Curiosities -- Familial Non-haemolytic Hyperbilirubinaemias -- Gilbert's Syndrome -- Background -- Diagnosis -- Treatment -- Prognosis -- Alagille Syndrome -- Background -- Diagnosis -- Treatment -- Prognosis -- Caroli Disease -- Background -- Diagnosis -- Prognosis and Treatment -- Benign

Recurrent Intrahepatic Cholestasis (BRIC) and Progressive Familial
Intrahepatic Cholestasis (PFIC) -- Background -- Diagnosis --
Treatment -- Prognosis -- Amyloidosis -- Background -- Diagnosis --
Treatment -- Prognosis -- Sarcoidosis -- Background -- Diagnosis --
Treatment and Prognosis -- Budd-Chiari Syndrome -- Background --
Diagnosis -- Treatment -- Prognosis -- Hepato-pulmonary Syndrome
-- Background -- Diagnosis -- Investigations -- Treatment.
Porto-pulmonary Hypertension.
